



Communication Address:

Solara Active Pharma Sciences Limited
2nd Floor, Admin Block
27, Vandaloor Kelambakkam Road,
Keelakottaiyur Village, Melakottaiyur (Post)
Chennai – 600 127, India
Tel : +91 44 43446700
Fax : +91 44 47406190
E-mail : investors@solara.co.in
www.solara.co.in

November 01, 2022

The BSE Limited

Phiroze Jeejeebhoy Towers,
Dalal Street, Mumbai - 400 001

Scrip Code: 541540

The National Stock Exchange of India Limited

Exchange Plaza BandraKurla Complex Sandra (E)
Mumbai - 400 051

Scrip Code: SOLARA

Dear Sir/ Madam,

Sub: Press release - Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulation, 2015

Please find attached press release issued by the Company titled:

“Solara receives European Approval (CEP) to manufacture Ibuprofen from its flagship Vizag facility”

Thanking you,
Yours Truly,

For Solara Active Pharma Sciences Limited

S. Murali Krishna
Company Secretary

Encl. as above

Solara receives European Approval (CEP) to manufacture Ibuprofen from its flagship Vizag Facility

Chennai, India – November 01, 2022: Solara Active Pharma Sciences Limited (Solara), a leading pure play Active Pharmaceutical Ingredient provider is pleased to announce that its new state of the art multipurpose API manufacturing facility at Vishakhapatnam, Andhra Pradesh, had received 'Certificate of Suitability' (CEP) approval for the manufacture of Ibuprofen API, from European Directorate for the Quality of Medicines (EDQM), the first international regulatory approval for this new facility.

With this key approval, Solara has CEP approval for two manufacturing facilities for Ibuprofen API, the other being its dedicated manufacturing facility located at Puducherry, India.

Solara also expects series of other international regulatory approvals for its Vizag facility, including USFDA.

Commenting on the CEP approval, Jitesh Devendra, MD said *"We are very happy to announce the CEP approval of Ibuprofen for our Vizag facility. With this, we can offer Ibuprofen to our customers in Europe from our Vizag facility and our current Pondicherry facility. The timing of approval is in line with the demand of Ibuprofen normalizing to its original levels further strengthening Solara's leadership position in the regulated markets.*

In addition to Ibuprofen API, we have commenced validation of new API's to be filed from Vizag in the next few quarters for various regulated markets which will result in offsetting the under recoveries.

Vizag site plays a pivotal role in our long-term growth strategy. We remain committed towards this effort."

About Solara

Solara Active Pharma Sciences Ltd (BSE-541540, NSE-SOLARA) is a pure play global API manufacturer supported by state-of-the-art R&D and manufacturing facilities. With 6 manufacturing facilities and an R&D centre, Solara offers a basket of diversified, high-value Commercial APIs and Contract manufacturing services. Its API facilities are approved by various international regulatory agencies including the USFDA, EDQM, MFDS, WHO, PMDA etc.

Investor / Analyst contact

Abhishek Singhal

✉ abhishek.singhal@solara.co.in

☎ +91 99877 66968

Statutory and corporate affairs

Murali Krishna S

Raghavan. V

✉ investors@solara.co.in

Disclaimer: Certain statements in this document are not historical facts and are forward-looking statements. Such forward-looking statements are subject to certain risks and uncertainties like government actions, local, political, or economic developments, technological risks, and many other factors that could cause actual results to differ materially from those contemplated by the relevant forward-looking statements. Solara Active Pharma Sciences Ltd will not be in any way responsible for any action taken based on such statements and undertakes no obligation to publicly update these forward-looking statements to reflect subsequent events or circumstances.